- Home » News and EventsPage 4
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Apr 13, 2021
Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Apr 6, 2021
Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.
Catalent Expands Partnership with Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing and Packaging of COVID-19 Vaccine in Italy
Mar 17, 2021
Catalent today announced Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy.
Catalent joins the EuropaBio 25th Anniversary in 2021
Mar 9, 2021
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities
Feb 23, 2021
Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy.
Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy
Feb 8, 2021
Catalent today announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.
Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss
Feb 4, 2021
Catalent and Decibel Therapeutics today announced they have signed an agreement for Catalent to provide Decibel with process and analytical development, and CGMP clinical manufacturing services, for Decibel’s lead investigational gene therapy product candidate, DB-OTO.
Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products
Dec 7, 2020
Passage Bio, Inc. and Catalent today announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic CNS disorders.
Catalent Appoints Dr. Behzad Mahdavi as Vice President of Open Innovation, Biologics, Cell and Gene Therapy
Nov 19, 2020
Catalent appoints Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. Dr. Mahdavi will join a team of experts to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.